Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06106256 · ClinicalTrials.gov registry record · NA
Three-Axis Wearable Adaptive Vestibular Stimulator
A NA study of Motion Sickness, sponsored by Mayo Clinic.
- Active
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06106256 is a NA study of Motion Sickness that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 40 participants, below the 149-participant average among 6 other Motion Sickness trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06106256, a NA study of Motion Sickness, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to improve current galvanic vestibular stimulation (GVS) technology to ease the motion sickness often associated with virtual reality (VR) simulation.
Conditions Studied
Interventions
- DEVICE Galvanic Vestibular Stimulation (GVS)
- OTHER Flight simulations in virtual reality (VR)
- OTHER 3-DOF Bertec Portable Essential's dual-balance force plate system
Study Locations (1)
Arizona
- Mayo Clinic Arizona - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-11-15 |
| Est. Completion | 2026-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06106256
The ClinicalTrials.gov registry entry for NCT06106256 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 149-participant average among 6 other Motion Sickness trials with a reported enrollment target (73% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Motion Sickness appearing as the primary indexed condition, and to 3 interventions - of which Galvanic Vestibular Stimulation (GVS) is the first listed.
NCT06106256 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT06106256 about?
NCT06106256 is a clinical study titled "Three-Axis Wearable Adaptive Vestibular Stimulator". The purpose of this study is to improve current galvanic vestibular stimulation (GVS) technology to ease the motion sickness often associated with virtual reality (VR) simulation.
What is the current status of trial NCT06106256?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2023-11-15. Estimated completion is 2026-12.
What conditions does trial NCT06106256 study?
This clinical trial studies the following conditions: Motion Sickness.
What interventions are being tested in trial NCT06106256?
The interventions under investigation include: Galvanic Vestibular Stimulation (GVS) (DEVICE), Flight simulations in virtual reality (VR) (OTHER), 3-DOF Bertec Portable Essential's dual-balance force plate system (OTHER).
Who is sponsoring clinical trial NCT06106256?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06106256 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Motion Sickness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
StableEyes With Active Neurofeedback
RECRUITING · NA
-
Evaluation of a Device to Reduce Motion Sickness and Spatial Disorientation
RECRUITING · NA
-
Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
RECRUITING · Phase 2
-
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness
ACTIVE NOT RECRUITING · Phase 3
-
Vestibulo-Ocular Reflex Function in Individuals With Chronic Motion Sensitivity Cross-Sectional Study
COMPLETED
-
Nebulizer Delivery of Intranasal Scopolamine
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.